New Haven, United States
Simcha Therapeutics is a clinical-stage biotechnology startup founded in 2018 and headquartered in the United States. The company's slogan "Overcoming biological challenges in clinically translatable pathways" reflects its focus on pioneering first-in-class engineered cytokine therapeutics. Their lead program, ST-067, which is the first decoy-resistant interleukin-18 (IL-18), shows transformational promise as a monotherapy and in combination with other anticancer agents. Currently in a Phase 1/2 clinical trial for patients with solid tumors who have progressed on other immunotherapeutic agents, ST-067 is receiving significant attention.
The company's innovative approach to immune-biology and cytokine engineering has broad potential to support disease-modifying therapeutic options for a range of significant diseases. Moreover, Simcha Therapeutics recently secured a substantial $40.00M Series B investment on 27 January 2022, with notable investors including ArrowMark Partners, BVF Partners, Logos Capital, Rock Springs Capital, Samsara BioCapital, and SR One. This infusion of capital positions Simcha well to advance its promising pipeline and further its mission to address unmet medical needs through groundbreaking immunobiology innovations.
